Skip to main content
Premium Trial:

Request an Annual Quote

Almac, Merck KGaA Partner on Cetuximab Markers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almac Diagnostics will collaborate with Merck KGaA and the Medical Research Council on a study of potential biomarkers of response to the cancer drug cetuximab (Erbitux).

The partners will use metastatic colon cancer samples from the MRC's COIN trial — a phase III, multicenter, three-arm study of first-line treatment of metastatic colon cancer — to assess the potential biomarkers. Cetuximab has been approved in Europe in combination with standard chemotherapy as a first-line treatment for mCRC in patients with KRAS wildtype tumors.

Craigavon, Northern Ireland-based Almac said that it will conduct quantitative PCR profiling and data analysis of the samples and assess potential biomarkers, beyond KRAS, in the context of combination therapy with cetuximab.

Further terms of the alliance were not disclosed.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.